Stonepine Capital Management LLC Trims Holdings in ADMA Biologics Inc $ADMA

Key Points

• Stonepine Capital Management LLC reduced its stake in ADMA Biologics by 34.7%, now holding 810,000 shares, which represents 15.4% of their overall portfolio.
• Brokerages have had mixed opinions on ADMA Biologics; while Wall Street Zen downgraded the stock to a "sell," Raymond James Financial raised its price target and rated it a "strong buy."
• Insider sales included Director Steve Elms selling 194,749 shares, a 69.04% decrease in his position, highlighting activity among corporate insiders amidst stock fluctuations.

Stonepine Capital Management LLC decreased its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 34.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 810,000 shares of the biotechnology company's stock after selling 431,032 shares during the period. ADMA Biologics accounts for about 15.4% of Stonepine Capital Management LLC's holdings, making the stock its largest holding. Stonepine Capital Management LLC owned about 0.34% of ADMA Biologics worth $16,070,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. New York State Teachers Retirement System grew its holdings in shares of ADMA Biologics by 96.2% during the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock worth $4,402,000 after acquiring an additional 108,800 shares during the period. GAMMA Investing LLC grew its holdings in shares of ADMA Biologics by 251.6% during the 1st quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock worth $131,000 after acquiring an additional 4,715 shares during the period. Concurrent Investment Advisors LLC purchased a new position in shares of ADMA Biologics during the 1st quarter worth approximately $201,000. Ameriprise Financial Inc. grew its stake in shares of ADMA Biologics by 14.1% in the 4th quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock worth $12,274,000 after buying an additional 88,542 shares during the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $2,293,000. Institutional investors own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the transaction, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares in the company, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 455,621 shares of company stock valued at $9,461,633. Company insiders own 3.50% of the company's stock.

ADMA Biologics Stock Performance

Shares of ADMA stock traded down $0.12 on Friday, reaching $17.26. The stock had a trading volume of 740,156 shares, compared to its average volume of 3,096,091. The stock has a market cap of $4.12 billion, a P/E ratio of 20.06 and a beta of 0.38. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The company has a 50 day simple moving average of $17.77 and a 200 day simple moving average of $18.88.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company's revenue for the quarter was up 13.8% on a year-over-year basis. During the same period last year, the business posted $0.13 EPS. Equities research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ADMA shares. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.